Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines

被引:61
作者
Cleland, JL [1 ]
机构
[1] Genentech Inc, S San Francisco, CA 94080 USA
关键词
D O I
10.1021/bp970128t
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Novel drug delivery technologies have now evolved to allow the clinical production of new dosage forms. One new form, biodegradable microspheres, may have utility as a second-generation formulation for parenterally administered proteins and peptides br may be required for the success of some new chemical entities. Here, we have focused on the use of poly(lactic-co-glycolic acid) (PLGA) microspheres to provide a continuous delivery of therapeutic proteins or a pulsatile delivery of protein-based vaccines. To date, our success with solvent evaporation processes has been primarily in the production of microspheres with a triphasic protein release pattern instead of a continuous release. However, with continued development efforts, this method may be used to produce continuous release protein formulations. While this review draws from our own work, there is a great deal of excellent research in this area at both universities and industrial laboratories. This work combined with our studies indicates that this technology holds much promise for new protein formulations that will provide improvements in patient care and, perhaps, increased efficacy.
引用
收藏
页码:102 / 107
页数:6
相关论文
共 22 条
[11]  
CLELAND JL, 1994, ACS SYM SER, V567, P1
[12]  
CLELAND JL, 1997, IN PRESS J CONTROLLE
[13]  
CLELAND JL, 1996, PHARMACEUT RES, V13, P1462
[14]  
KASLOW DC, 1994, BIO-TECHNOL, V12, P494, DOI 10.1038/nbt0594-494
[15]  
Kissel T., 1996, MICROPARTICULATE SYS, P51
[16]   POTENTIAL OF POLYMER MICROENCAPSULATION TECHNOLOGY FOR VACCINE INNOVATION [J].
MORRIS, W ;
STEINHOFF, MC ;
RUSSELL, PK .
VACCINE, 1994, 12 (01) :5-11
[17]   PHARMACOKINETICS OF ONCE-A-MONTH INJECTABLE MICROSPHERES OF LEUPROLIDE ACETATE [J].
OKADA, H ;
INOUE, Y ;
HEYA, T ;
UENO, H ;
OGAWA, Y ;
TOGUCHI, H .
PHARMACEUTICAL RESEARCH, 1991, 8 (06) :787-791
[18]  
Schwendeman S.P., 1997, CONTROLLED DRUG DELI, P229
[19]   Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer [J].
Sharifi, R ;
Bruskewitz, RC ;
Gittleman, MC ;
Graham, SD ;
Hudson, PB ;
Stein, B .
CLINICAL THERAPEUTICS, 1996, 18 (04) :647-657
[20]   DIFFERENTIAL REGULATION OF SERUM GROWTH-HORMONE (GH)-BINDING PROTEIN DURING CONTINUOUS-INFUSION VERSUS DAILY INJECTION OF RECOMBINANT HUMAN GH IN GH-DEFICIENT CHILDREN [J].
TAUBER, M ;
DUPORTAL, HD ;
SALLERINCAUTE, B ;
ROCHICCIOLI, P ;
BASTIDE, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (05) :1135-1139